Objective To explore the effect and side effects of dezocine combined with sufentanil in patient-controlled intravenous analgesia(PCIA)of elderly patients with radical resec-tion of gastroenteric tumor.Methods 60 elderly patients with selective radical operation for gas-troenteric tumor were randomly divided into dezocine combined with sufentanil group (group DS,n=30)and sufentanil group (group S,n =30).Continuous monitoring was used to record blood pressure,heart rate,respiratory rate and SpO2,the VAS scores during both silence and 90°turn over situation were recorded,and Ramsay scores at 4,8,16,24 and 48 hours after operation as well as the adverse reactions were compared.Results There were no significant differences of Ramsay score and VAS pain during silence between two groups,but there was a significant differ-ence of VAS pain under turn-over situation between two groups(P <0.05).In group SD,the in-cidence rates of side effects such as nausea,vomiting,dizziness and shivering were significantly low-er than those in group S(P <0.05).Conclusion Application of dezocine combined with sufentanil has a preferable therapeutic effect for post-operative movement pain and less adverse effects,and it is worthy of clinical application and popularization.

Objective To explore the effect and side effects of dezocine combined with sufentanil in patient-controlled intravenous analgesia(PCIA)of elderly patients with radical resec-tion of gastroenteric tumor.Methods 60 elderly patients with selective radical operation for gas-troenteric tumor were randomly divided into dezocine combined with sufentanil group (group DS,n=30)and sufentanil group (group S,n =30).Continuous monitoring was used to record blood pressure,heart rate,respiratory rate and SpO2,the VAS scores during both silence and 90°turn over situation were recorded,and Ramsay scores at 4,8,16,24 and 48 hours after operation as well as the adverse reactions were compared.Results There were no significant differences of Ramsay score and VAS pain during silence between two groups,but there was a significant differ-ence of VAS pain under turn-over situation between two groups(P <0.05).In group SD,the in-cidence rates of side effects such as nausea,vomiting,dizziness and shivering were significantly low-er than those in group S(P <0.05).Conclusion Application of dezocine combined with sufentanil has a preferable therapeutic effect for post-operative movement pain and less adverse effects,and it is worthy of clinical application and popularization.

Objectives: To analyze lung cancer data of patients who are registered in Zhejiang province from 2010 to 2014 and describe the prevalence and mortality of lung cancer in residents of Zhejiang province, so as to provide a reference basis for the government and health administrative departments to formulate a strategy of cancer prevention and treatment. Methods: According to the report of 14 tumor registries of Zhejiang province from 2010 to 2014 in urban and rural areas, lung cancer incidence and mortality were calculated by gender, age, and urban or rural areas, respectively. The population structure from the 2000 national census and Segi's standard population was used to calculate the standardized rates and indicators such as the 0-74-year-old accumulation rates and 35-64-year-old truncation rates. Results: In 2010-2014, there were 37,227 new cases of malignant tumors of the trachea, bronchi, and lungs in Zhejiang cancer registration areas (which are referred to as lung cancer in this article; ICD10 was coded as c33-c34), with the crude incidence rates of 63.55 per 100,000, 35.73 per 100,000 for ASR China, and 35.54 per 100,000 for ASR world, accounting for 18.85% of all cancer cases. The cu-mulative rate of incidence in those aged 0-74 years was 4.44%. Of the new cases, 25,608 were men and 11,619 were women. The ASR China in male was as 2.26 times high as that in female. The ASR China in rural areas was as 1.12 times high as that in urban areas. There were 31,772 deaths in 2010-2014, with the crude mortality rates of 54.24 per 100,000, 29.39 per 100,000 for ASR China, and 29.05 per 100,000 for ASR world, accounting for 29.22% of all cancer deaths. Of the deaths, 22,796 were men and 8,976 were women. The ASR China in male was as 2.70 times high as that in female. The ASR China in rural areas was as 1.05 times high as that in urban areas. The age-specific incidence and mortality rates were relatively low before 40 years old, and increased dramatically after 40 years old, then reached peak at the age of 80 years old. Rates in male were generally higher than those in female. The age-specific incidence and mortality rates varied in urban and rural areas with similar curves. Conclusions: Lung cancer was the most common malignancy in Zhejiang province, and its incidence and mortality are both in the first place of all cancers . With the relatively high burden of disease, lung cancer should be regarded as one of the key malignant tumors while developing strategies for cancer prevention and treatment.

Objective:To evaluate the clinical performance of anti-peptidylarginine deiminase 2 (PAD2) and anti-PAD4 antibodies combined testing in a Chinese rheumatoid arthritis (RA) cohort.Methods:A total of 148 RA inpatients and 35 patients with non-RA arthritis as controls (DC) were recruited from November, 2018 to November, 2019 in Peking University People′s Hospital. In addition, a total of 44 healthy controls (HC) who went to Peking University People′s Hospital for annual physical examination were collected from June 2019 to July 2019. The α-PAD2 and α-PAD4 level in clinical specimens were determined by ELISA. Statistical analysis was performed by the Mann-Whitney U test, the Kruskal-Wallis (KW) test, the χ 2 test or the Fisher′s Exact Test, as necessary. Correlation analysis were performed by logistic regression. Results:α-PAD2 and α-PAD4 were present in 26.4% (39/148) and 20.9% (31/148) patients with RA, 5.7% (2/35) and 5.7% DC (2/35) and 4.5% (2/44) and 2.3% HC (2/44), respectively. α-PAD4-positive RA patients displayed significantly longer disease duration compared to α-PAD4-negative RA patients (17.3±13.2 years vs 8.6±10.2 years, P<0.001). α-PAD4-positive RA patients showed a significantly higher incidence of interstitial lung disease (ILD) compared to those without α-PAD4 (54.8% vs 25.6%, P=0.002). No associations between α-PAD2 and ILD were found ( OR: 0.797, P=0.579). In contrast, significant associations between α-PAD4 and ILD were found ( OR: 3.521, P=0.002). In seropositive RA, α-PAD4 displayed a weak correlation with ILD ( OR: 2.324, P=0.046), but this association was greatly enhanced when combined with α-PAD2 [anti-PAD2 (-)] ( OR: 4.059, P=0.007). Conclusions:The findings delineate the clinical relevance of α-PAD2 and α-PAD4 in RA and suggest that the combined testing for α-PAD2 and α-PAD4 may provide additional diagnostic value to the current clinically available assays in RA, in particular in identifying patients at risk of RA-ILD.

From 2010 to 2014, a total of 17 150 new cases of thyroid cancer (TC) reported in cancer registration areas of Zhejiang province, the crude incidence rate of TC was 29.28/100 000. Using the Chinese Census in 2000 and the World Segi′s population as the standard population, the age?standardized incidence rate by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 24.11/100 000 and 20.65/100 000 respectively. 256 TC death cases reported in all, the crude mortality rate was 0.44/100 000, the age?standardized mortality rate by Chinese standard population (ASMRC) and by World standard population (ASMRW) were 0.23/100 000 and 0.23/100 000 respectively. The ASIRC had a upward trend [annual percent change (APC)=28.62%, 95%CI : 21.00%-36.72%, t=13.10, P=0.001], while the ASMRC trend seemed stable (APC=0.73%, 95%CI :-7.47%-9.66%, t=0.27, P=0.803).

The incidence and mortality rate of leukemia in the cancer registration areas of Zhejiang Province from 2010 to 2014 were analyzed to depict their epidemiological characteristics. From 2010 to 2014, 3789 new cases were diagnosed as leukemia in Zhejiang cancer registration areas, with a crude incidence rate of 6.47 per 100 000. The age?standardized incidence rate of males (standardized by China census data 2000) was 1.35 times that of females. The age?standardized incidence rate of urban areas was similar to that in rural areas (1.04∶1). From 2010 to 2014, 2 568 cases died due to leukemia, with a crude mortality rate of 4.38 per 100 000. The age?standardized mortality rate of males was 1.44 times that of females. The age?standardized mortality rate of urban areas was 0.99 times that of rural areas. The age?standardized incidence and mortality rate did not show any significant change from 2010 to 2014. The annual percent change of these two metrics was-2.36% (t=-0.62, P=0.579) and-3.46% (t=-2.41, P=0.095).

From 2010 to 2014, a total of 17 150 new cases of thyroid cancer (TC) reported in cancer registration areas of Zhejiang province, the crude incidence rate of TC was 29.28/100 000. Using the Chinese Census in 2000 and the World Segi′s population as the standard population, the age?standardized incidence rate by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 24.11/100 000 and 20.65/100 000 respectively. 256 TC death cases reported in all, the crude mortality rate was 0.44/100 000, the age?standardized mortality rate by Chinese standard population (ASMRC) and by World standard population (ASMRW) were 0.23/100 000 and 0.23/100 000 respectively. The ASIRC had a upward trend [annual percent change (APC)=28.62%, 95%CI : 21.00%-36.72%, t=13.10, P=0.001], while the ASMRC trend seemed stable (APC=0.73%, 95%CI :-7.47%-9.66%, t=0.27, P=0.803).

The incidence and mortality rate of leukemia in the cancer registration areas of Zhejiang Province from 2010 to 2014 were analyzed to depict their epidemiological characteristics. From 2010 to 2014, 3789 new cases were diagnosed as leukemia in Zhejiang cancer registration areas, with a crude incidence rate of 6.47 per 100 000. The age?standardized incidence rate of males (standardized by China census data 2000) was 1.35 times that of females. The age?standardized incidence rate of urban areas was similar to that in rural areas (1.04∶1). From 2010 to 2014, 2 568 cases died due to leukemia, with a crude mortality rate of 4.38 per 100 000. The age?standardized mortality rate of males was 1.44 times that of females. The age?standardized mortality rate of urban areas was 0.99 times that of rural areas. The age?standardized incidence and mortality rate did not show any significant change from 2010 to 2014. The annual percent change of these two metrics was-2.36% (t=-0.62, P=0.579) and-3.46% (t=-2.41, P=0.095).

From 2010 to 2014, a total of 17 150 new cases of thyroid cancer (TC) reported in cancer registration areas of Zhejiang province, the crude incidence rate of TC was 29.28/100 000. Using the Chinese Census in 2000 and the World Segi′s population as the standard population, the age-standardized incidence rate by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 24.11/100 000 and 20.65/100 000 respectively. 256 TC death cases reported in all, the crude mortality rate was 0.44/100 000, the age-standardized mortality rate by Chinese standard population (ASMRC) and by World standard population (ASMRW) were 0.23/100 000 and 0.23/100 000 respectively. The ASIRC had a upward trend [annual percent change (APC)=28.62%, 95%CI: 21.00%-36.72%, t=13.10, P=0.001], while the ASMRC trend seemed stable (APC=0.73%, 95%CI: -7.47%-9.66%, t=0.27, P=0.803).

The incidence and mortality rate of leukemia in the cancer registration areas of Zhejiang Province from 2010 to 2014 were analyzed to depict their epidemiological characteristics. From 2010 to 2014, 3789 new cases were diagnosed as leukemia in Zhejiang cancer registration areas, with a crude incidence rate of 6.47 per 100 000. The age-standardized incidence rate of males (standardized by China census data 2000) was 1.35 times that of females. The age-standardized incidence rate of urban areas was similar to that in rural areas (1.04∶1). From 2010 to 2014, 2 568 cases died due to leukemia, with a crude mortality rate of 4.38 per 100 000. The age-standardized mortality rate of males was 1.44 times that of females. The age-standardized mortality rate of urban areas was 0.99 times that of rural areas. The age-standardized incidence and mortality rate did not show any significant change from 2010 to 2014. The annual percent change of these two metrics was -2.36% (t=-0.62, P=0.579) and -3.46% (t=-2.41, P=0.095).